An Overview of Modified Chitosan Adsorbents for the Removal of Precious Metals Species from Aqueous Media.

This mini-review provides coverage of chitosan-based adsorbents and their modified forms as sustainable solid-phase extraction (SPE) materials for precious metal ions, such as gold species, and their complexes in aqueous media. Modified forms of chitosan-based adsorbents range from surface-functionalized systems to biomaterial composites that contain inorganic or other nanomaterial components. An overview of the SPE conditions such as pH, temperature, contact time, and adsorbent dosage was carried out to outline how these factors affect the efficiency of the sorption process, with an emphasis on gold species. This review provides insight into the structure-property relationships for chitinaceous adsorbents and their metal-ion removal mechanism in aqueous media. Cross-linked chitosan sorbents showed a maximum for Au(III) uptake capacity (600 mg/g), while S-containing cross-linked chitosan display favourable selectivity and uptake capacity with Au(III) species. Compared to industrial adsorbents such as activated carbon, modified chitosan sorbents display favourable uptake of Au(III) species, especially in aqueous media at low pH. In turn, this contribution is intended to catalyze further research directed at the rational design of tailored SPE materials that employ biopolymer scaffolds to yield improved uptake properties of precious metal species in aqueous systems. The controlled removal of gold and precious metal species from aqueous media is highly relevant to sustainable industrial processes and environmental remediation.

Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.

The JULIET phase 2 trial evaluated a single infusion of tisagenlecleucel in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The objective of the current analysis was to evaluate patient-reported health-related quality of life (HRQoL) with a median follow-up of 19.3 months among patients infused with a single dose of tisagenlecleucel. Patients enrolled were ≥18 years of age with r/r DLBCL after ≥2 lines of therapy and had either undergone a failed autologous stem cell transplant or were ineligible for the procedure. Two validated HRQoL instruments, Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and Short Form-36 (SF-36) Health Survey, were used to measure HRQoL at baseline and months 3, 6, 12, and 18. At data cutoff (21 May 2018), 115 patients had received tisagenlecleucel infusion. Among the 99 patients evaluated, overall response rate was 54%, and 40% of patients achieved complete response (CR). Initially, 108 patients completed the HRQoL assessments at baseline, including 57 patients who eventually achieved CR or partial response (PR). Further, 30 and 21 patients in clinical response who completed assessments at baseline also completed assessments at months 12 and 18, respectively. Patients who achieved CR or PR sustained HRQoL improvement in all FACT scores at all time points. SF-36 instruments showed improvement above the minimal clinically important differences on 5 of 8 subscales. Long-term follow-up in the phase 2 JULIET study demonstrated that patients with r/r DLBCL who respond to tisagenlecleucel therapy had sustained, clinically meaningful improvements in HRQoL. This trial was registered at www.clinicaltrials.gov as #NCT02445248.

How we treat thrombotic thrombocytopenic purpura: Results of a Canadian TTP practice survey.

BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) is a rare disease with 90% mortality if untreated. Since the Canadian Apheresis Group (CAG) trial showed greater survival with therapeutic plasma exchange (TPE) versus plasma infusion, there has been widespread adoption of TPE. Beyond TPE, there is significant practice variation. To characterize this, we developed a survey sent to physicians who might be directly involved in TTP management. METHODS: The survey was sent to CAG members as well as hematologists and nephrologists nationwide and addressed areas of controversy or recognized practice heterogeneity. Descriptive statistics were used to summarize responses, and the χ2 test was used to compare respondents who were and were not CAG physicians. We also compared responses by estimated frequency of TTP cases per year. RESULTS: The CAG response rate was 31% (13 of 42). The survey was sent to 665 non-CAG physicians, of whom 41 responded (6.1%). Though not statistically different, CAG and non-CAG respondents varied regarding use of corticosteroids, aspirin, and venous thromboembolism (VTE) prophylaxis. Significant differences were found between CAG and non-CAG groups regarding cryosupernatant as fluid choice (69.2% vs. 22.5%, P = .004) and the use of TPE tapering (84.6% vs. 51.3%, P = .034), respectively. CONCLUSION: TTP treatment is variable across centres in Canada. Areas of significant variation include the choice of replacement fluid for TPE and whether or not and how to taper TPE. Our survey highlights the practice heterogeneity that exists and identifies areas where more evidence is needed and perhaps where trials should be performed.

Bis-diimidazolylidine complexes of nickel: investigations into nickel catalyzed coupling reactions.

Air and moisture stable homoleptic bis(diimidazolylidine)nickel(II) complexes, ([(diNHC)(2)Ni](2+)) 3a,b and their corresponding silver(I) 4a,b and palladium(II) 5a,b complexes were synthesized and characterized by NMR and single crystal X-ray analysis. The catalytic potential of complex 3a was assessed in Mizoroki-Heck and Suzuki-Miyaura coupling reactions. In the Suzuki-Miyaura coupling reaction, nickel precatalyst 3a was active for the coupling of aryl chlorides as well as aryl fluorides. The analogously synthesized Pd(II) complexes resulted in formation of (diNHC)PdCl(2) species which were not active for the coupling of aryl fluorides. For the Mizoroki-Heck reaction, it was found that aryl iodides could be activated in the absence of nickel or palladium precatalysts when using Na(2)CO(3) or NEt(3) as base while aryl iodides and aryl bromides could be activated in the Suzuki-Miyaura reaction sans precatalyst when K(3)PO(4) was used as base.

A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura.

Rituximab is a chimeric monoclonal antibody that targets the human CD-20 antigen present on malignant and normal B lymphocytes. Recent clinical studies have shown a significant response rate when this drug is given to selected patients with thrombotic thrombocytopenic purpura (TTP). Given that the clinical manifestations of TTP may be the direct result of an auto-antibody against a regulatory Von Willebrand factor enzyme (ADAMTS13), it makes biological sense to consider a therapy that has the ability to diminish or eradicate antibody-producing B cells. Despite initial positive results, there is a need to identify which patients derive durable benefit from this agent. As in other conditions that utilize therapeutic immunosuppression, there is a risk that the addition of rituximab may also lead to serious opportunistic infections.

Synthesis of palladacycles employing iminoisoindolines as monoanionic bidentate ligands.

A series of air- and moisture-stable iminoisoindoline-based palladacycles have been prepared in two operationally simple steps from commercially available reagents. para-Substituted N,N'-diphenyliminoisoindoline ligands are easily synthesized from phthalaldehyde and para-substituted anilines and further reaction of the iminoisoindoline ligands with Pd(OAc)(2) in dichloromethane at room temperature results in formation of six-membered [C,N] dinuclear cyclopalladated complexes with the general formula [(iminoisoindoline)Pd(micro-OAc)](2). The resulting palladacyclic complexes were tested as precatalysts in Heck and Suzuki coupling reactions.

N-(2,6-Diisopropyl-phen-yl)formamide.

The title compound, C(13)H(19)NO, exhibits a non-planar structure in which the 2,6-diisopropyl-phenyl ring is tilted at a dihedral angle of 77.4 (1)° with respect to the formamide group. This is the largest dihedral angle known among structurally characterized formamides. The mol-ecules are linked via N-H⋯O hydrogen bonds, forming infinite chains which run along the b-axis directions.

Bis[2-phenyl-1-(phenyl-iminio)isoindo-line] di-µ-chlorido-bis-[dichloridopalladate(II)] benzene disolvate.

In the title compound, (C(20)H(17)N(2))(2)[Pd(2)Cl(6)]·2C(6)H(6), the dichloride-bridged [Pd(2)Cl(6)](2-) anion lies across an inversion center with each Pd(II) ion in a slightly distorted square-planar environment. In the crystal structure, two cations and an anion are connected via N-H⋯Cl hydrogen bonds between the NH groups of the iminioisoindoline cations and terminal Cl atoms of a hexa-chloridodipalladate(II) anion. The Pd-Cl distance of the terminal chloride engaged in hydrogen bonding is slightly longer than the Pd-Cl distance of the adjacent terminal chloride which is not involved in hydrogen bonding.

Acrylonitrile insertion reactions of cationic palladium alkyl complexes.

The reactions of acrylonitrile (AN) with "L(2)PdMe+" species were investigated; (L(2) = CH(2)(N-Me-imidazol-2-yl)(2) (a, bim), (p-tolyl)(3)CCH(N-Me-imidazol-2-yl)(2) (b, Tbim), CH(2)(5-Me-2-pyridyl)(2) (c, CH(2)py'(2)), 4,4'-Me(2)-2,2'-bipyridine (d), 4,4'-(t)Bu(2)-2,2'-bipyridine (e), (2,6-(i)Pr(2)-C(6)H(3))N=CMeCMe=N(2,6-(i)Pr(2)-C(6)H(3)) (f)). [L(2)PdMe(NMe(2)Ph)][B(C(6)F(5))(4)] (2a-c) and [{L(2)PdMe}(2)(mu-Cl)][B(C(6)F(5))(4)] (2d-f) react with AN to form N-bound adducts L(2)Pd(Me)(NCCH=CH(2))(+) (3a-f). 3a-e undergo 2,1 insertion to yield L(2)Pd{CH(CN)Et}+, which form aggregates [L(2)Pd{CH(CN)Et}](n)(n)(+) (n = 1-3, 4a-e) in which the Pd units are proposed to be linked by PdCHEtCN- - -Pd bridges. 3f does not insert AN at 23 degrees C. 4a-e were characterized by NMR, ESI-MS, IR and derivatization to L(2)Pd{CH(CN)Et}(PR(3))+ (R = Ph (5a-e), Me (6a-c)). 4a,b react with CO to form L(2)Pd{CH(CN)Et}(CO)+ (7a,b). 7a reacts with CO by slow reversible insertion to yield (bim)Pd{C(=O)CH(CN)Et}(CO)+ (8a). 4a-e do not react with ethylene. (Tbim)PdMe+ coordinates AN more weakly than ethylene, and AN insertion of 3b is slower than ethylene insertion of (Tbim)Pd(Me)(CH(2)=CH(2))(+) (10b). These results show that most important obstacles to insertion polymerization or copolymerization of AN using L(2)PdR+ catalysts are the tendency of L(2)Pd{CH(CN)CH(2)R}+ species to aggregate, which competes with monomer coordination, and the low insertion reactivity of L(2)Pd{CH(CN)CH(2)R}(substrate)+ species.

Acrylonitrile polymerization by Cy3PCuMe and (Bipy)2FeEt2.

Cy(3)PCuMe (1) undergoes reversible ligand redistribution at low temperature in solution to form the tight ion pair [Cu(PCy(3))(2)][CuMe(2)] (3). The structure of 3 was assigned on the basis of (i) the stoichiometry of the 1 = 3 equilibrium, (ii) the observation of a triplet for the PCy(3) C1 (13)C NMR resonance due to virtual coupling to two (31)P nuclei, and (iii) reverse synthesis of 1 by combining separately generated Cu(PCy(3))(2)(+) and CuMe(2)(-) ions. Complex 1 and [Cu(PCy(3))(2)][PF(6)] (5) coordinate additional PCy(3) to form (Cy(3)P)(2)CuMe and [Cu(PCy(3))(3)][PF(6)], respectively, while 3 does not. Complex 1, free PCy(3), and (bipy)(2)FeEt(2) (2) each initiate the polymerization of acrylonitrile. In each case, the polyacrylonitrile contains branches that are characteristic of an anionic polymerization mechanism. The major initiator in acrylonitrile polymerization by 1 is PCy(3), which is liberated from 1. A transient iron hydride complex is proposed to initiate acrylonitrile polymerization by 2.

Reaction of vinyl chloride with late transition metal olefin polymerization catalysts.

The reactions of vinyl chloride (VC) with representative late metal, single-site olefin dimerization and polymerization catalysts have been investigated. VC coordinates more weakly than ethylene or propylene to the simple catalyst (Me(2)bipy)PdMe(+) (Me(2)bipy = 4,4'-Me(2)-2,2'-bipyridine). Insertion rates of (Me(2)bipy)Pd(Me)(olefin)(+) species vary in the order VC > ethylene > propylene. The VC complexes (Me(2)bipy)Pd(Me)(VC)(+) and (alpha-diimine)Pd(Me)(VC)(+) (alpha-diimine = (2,6-(i)Pr(2)[bond]C(6)H(3))N[double bond]CMeCMe[double bond]N(2,6-(i)Pr(2)[bond]C(6)H(3))) undergo net 1,2 VC insertion and beta-Cl elimination to yield Pd[bond]Cl species and propylene. Analogous chemistry occurs for (pyridine-bisimine)MCl(2)/MAO catalysts (M = Fe, Co; pyridine-bisimine = 2,6-[(2,6-(i)Pr(2)[bond]C(6)H(3))N[double bond]CMe](2)-pyridine) and for neutral (sal)Ni(Ph)PPh(3) and (P[bond]O)Ni(Ph)PPh(3) catalysts (sal = 2-[C(H)[double bond]N(2,6-(i)Pr(2)-C(6)H(3))]-6-Ph-phenoxide; P[bond]O = [Ph(2)PC(SO(3)Na)[double bond]C(p-tol)O]), although the initial metal alkyl VC adducts were not detected in these cases. These results show that the L(n)MCH(2)CHClR species formed by VC insertion into the active species of late metal olefin polymerization catalysts undergo rapid beta-Cl elimination which precludes VC polymerization. Termination of chain growth by beta-Cl elimination is the most significant obstacle to metal-catalyzed insertion polymerization of VC.

Reaction of vinyl chloride with group 4 metal olefin polymerization catalysts.

The reactions of three types of group 4 metal olefin polymerization catalysts, (C(5)R(5))(2)ZrX(2)/activator, (C(5)Me(5))TiX(3)/MAO (MAO = methylalumoxane), and (C(5)Me(4)SiMe(2)N(t)Bu)MX(2)/activator (M = Ti, Zr), with vinyl chloride (VC) and VC/propylene mixtures have been investigated. Two general pathways are observed: (i) radical polymerization of VC initiated by radicals derived from the catalyst and (ii) net 1,2 VC insertion into L(n)MR(+) species followed by beta-Cl elimination. rac-(EBI)ZrMe(mu-Me)B(C(6)F(5))(3) (EBI = 1,2-ethylenebis(indenyl)) reacts with 2 equiv of VC to yield oligopropylene, rac-(EBI)ZrCl(2), and B(C(6)F(5))(3). This reaction proceeds by net 1,2 VC insertion into rac-(EBI)ZrMe(+) followed by fast beta-Cl elimination to yield [rac-(EBI)ZrCl][MeB(C(6)F(5))(3)] and propylene. Methylation of rac-(EBI)ZrCl(+) by MeB(C(6)F(5))(3)(-) enables a second VC insertion/beta-Cl elimination to occur. The evolved propylene is oligomerized by rac-(EBI)ZrR(+) as it is formed. At high Al/Zr ratios, rac-(EBI)ZrMe(2)/MAO catalytically converts VC to oligopropylene by 1,2 VC insertion into rac-(EBI)ZrMe(+), beta-Cl elimination, and realkylation of rac-(EBI)ZrCl(+) by MAO; this process is stoichiometric in Al-Me groups. The evolved propylene is oligomerized by rac-(EBI)ZrR(+). Oligopropylene end group analysis shows that the predominant chain transfer mechanism is VC insertion/beta-Cl elimination/realkylation. In the presence of trace levels of O(2), rac-(EBI)ZrMe(2)/MAO polymerizes VC to poly(vinyl chloride) (PVC) by a radical mechanism initiated by radicals generated by autoxidation of Zr-R and/or Al-R species. CpTiX(3)/MAO (Cp = C(5)Me(5); X = OMe, Cl) initiates radical polymerization of VC in CH(2)Cl(2) solvent at low Al/Ti ratios under anaerobic conditions; in this case, the source of initiating radicals is unknown. Radical VC polymerization can be identified by the presence of terminal and internal allylic chloride units and other "radical defects" in the PVC which arise from the characteristic chemistry of PCH(2)CHCl(*) macroradicals. However, this test must be used with caution, since the defect units can be consumed by postpolymerization reactions with MAO. (C(5)Me(4)SiMe(2)N(t)Bu)MMe(2)/[Ph(3)C]][B(C(6)F(5))(4)] catalysts (M = Ti, Zr) react with VC by net 1,2 insertion/beta-Cl elimination, yielding [(C(5)Me(4)SiMe(2)N(t)Bu)MCl][B(C(6)F(5))(4)] species which can be trapped as (C(5)Me(4)SiMe(2)N(t)Bu)MCl(2) by addition of a chloride source. The reaction of rac-(EBI)ZrMe(2)/MAO or [(C(5)Me(4)SiMe(2)N(t)Bu)ZrMe][B(C(6)F(5))(4)] with propylene/VC mixtures yields polypropylene containing both allylic and vinylidene unsaturated chain ends rather than strictly vinylidene chain ends, as observed in propylene homopolymerization. These results show that the VC insertion of L(n)M(CH(2)CHMe)(n)R(+) species is also followed by beta-Cl elimination, which terminates chain growth and precludes propylene/VC copolymerization. Termination of chain growth by beta-Cl elimination is the most significant obstacle to metal-catalyzed insertion polymerization/copolymerization of VC.

Synthesis and characterization of iron complexes with monoanionic and dianionic N,N',N' '-trialkylguanidinate ligands.

Trisubstitued N,N',N' '-tri(alkyl)guanidinate anions have been used in the synthesis of a family of Fe(II) and Fe(III) complexes. Complexes FeCl[((i)PrN)(2)C(HN(i)Pr)](2) (1), [Fe[micro-((i)PrN)(2)C(HN(i)Pr)][((i)PrN)(2)C(HN(i)Pr)]](2) (2), and [Fe[mgr;-(CyN)(2)C(HNCy)][(CyN)(2)C(HNCy)]](2) (3) were prepared from the reaction of the appropriate lithium tri(alkyl)guanidinate and FeCl(3) or FeBr(2). The complex [FeBr[micro-(CyN)(2)C(HNCy)]](2) (4), an apparent intermediate in the formation of 3, has also been isolated and characterized. Complexes 1 and 2 react with alkyllithium reagents to yield products that depend on the identity of the reagent as well as the reaction stoichiometry. Reaction of 2 with MeLi (1:2 ratio) produces Li(2)[Fe[micro-((i)PrN)(2)C=N(i)Pr][((i)PrN)(2)C(HN(i)Pr)]](2) (5). Reaction of 1 with an equimolar amount of LiCH(2)SiMe(3) results in reduction to Fe(II) and generation of 2 while reaction with 4 LiCH(2)SiMe(3) proceeds by a combination of reduction, substitution, and deprotonation of guandinate to yield Li(4)(THF)(2)[Fe[((i)PrN)(2)CN(i)Pr](CH(2)SiMe(3))(2)](2) (7). Both complexes 5 and 7 posssess dianionic guanidinate ligands. The reaction of 2 with 1 equiv of LiCH(2)SiMe(3) generated Fe(2)[micro-((i)PrNCN(i)Pr)(2)(N(i)Pr)][((i)PrN)(2)C(HN(i)Pr)](2) (6). Compound 6 has a dianionic biguanidinate ligand derived from the coupling of the two bridging guanidinate ligands of 2.